|Bid||104.66 x 1800|
|Ask||104.71 x 900|
|Day's range||104.08 - 106.15|
|52-week range||62.55 - 113.41|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||38.59|
|Earnings date||29 Apr 2021 - 03 May 2021|
|Forward dividend & yield||5.20 (4.87%)|
|Ex-dividend date||14 Apr 2021|
|1y target est||121.80|
Buffett's Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) added AbbVie (NYSE: ABBV) to its portfolio in the third quarter of last year. What makes AbbVie so appealing to two very different investors like Buffett and Wood? It's pretty easy to figure out why Wood chose AbbVie for the ARK Genomic Revolution ETF.
More important than its financial results, the biopharmaceutical company announced results from a clinical trial and other developments regarding collaboration agreements with big-name drugmakers. Morphic Holding reported interim data from a phase 1 clinical trial for MORF-057, a potential medicine for inflammatory bowel disease (IBD).
Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion